Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skeletal Histomorphometry with Teriparatide vs Zoledronic Acid in Postmenopausal Osteoporosis
NCT00927186Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2009
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of teriparatide in osteoporosis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mineralizing Surface/Bone Surface in the Cancellous Compartment at 6 months. Started Jul 2009; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00927186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927186.